|
Incidence of adverse events (AEs), adverse reactions and serious AEs (SAEs) for the two vaccine groups |
|||
| Incidence, %(n) |
P-value |
||
|
|
|||
| Sub/MF59™ (n = 391) |
Subunit (n = 198) |
||
|
|
|||
| Local reactions |
24.0(94) |
15.2(30) |
0.012 |
| Systemic reactions |
10.7(42) |
9.6(19) |
0.666 |
| AEs |
6.1(24) |
6.6(13) |
0.840 |
| SAEs |
1.0(4) |
0.5(1) |
0.668 |
| Vaccine-related AEs (definitely, probably or possibly related to the vaccine) |
3.8(15) |
5.1(10) |
0.490 |
| Vaccine-related SAEs (definitely, probably or possibly related to the vaccine) |
0.3(1) |
0.0(0) |
1.000 |
|
Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine | |||
Li et al. Immunity & Ageing 2008 5:2 doi:10.1186/1742-4933-5-2 |
|||